Stay updated with breaking news from Label Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy – – Advancing Phase 2 trial of EDG-5506 in Becker muscular... -Today at 08:03 am- MarketScreener
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the...
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and
Operator: Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode.
Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipelinePH94B Phase 3 program for social anxiety disorder advancing towards important next stepsPH10 Phase 1 study initiated to facilitate plans for Phase 2B develo...